• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿那白滞素在难治性川崎病合并冠状动脉瘤中的有效性和安全性。

Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm.

作者信息

Guillaume Marie-Paule, Reumaux Héloïse, Dubos François

机构信息

1Pediatric Cardiology,CHU Lille and University of Lille,Lille,France.

2Pediatric Rheumatology Unit,CHU Lille and University of Lille,Lille,France.

出版信息

Cardiol Young. 2018 May;28(5):739-742. doi: 10.1017/S1047951117002864. Epub 2018 Feb 19.

DOI:10.1017/S1047951117002864
PMID:29455693
Abstract

Kawasaki disease is an acute self-limited vasculitis of unknown aetiology. The prognosis depends mainly on coronary damage. There is no consensus regarding optimal adjunctive therapeutics for refractory forms to treatment by intravenous immunoglobulins and corticosteroids. We report the case of an 18-month-old infant with refractory Kawasaki disease complicated by diffuse aneurysms of coronary arteries and successfully treated by anakinra with partial regression of coronary aneurysms.

摘要

川崎病是一种病因不明的急性自限性血管炎。预后主要取决于冠状动脉损伤。对于静脉注射免疫球蛋白和皮质类固醇治疗无效的难治性川崎病，目前尚无关于最佳辅助治疗方法的共识。我们报告了一例18个月大的难治性川崎病婴儿病例，该病例合并冠状动脉弥漫性动脉瘤，使用阿那白滞素成功治疗，冠状动脉瘤部分消退。

相似文献

1
Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm.阿那白滞素在难治性川崎病合并冠状动脉瘤中的有效性和安全性。
Cardiol Young. 2018 May;28(5):739-742. doi: 10.1017/S1047951117002864. Epub 2018 Feb 19.
2
Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).阿那白滞素用于川崎病合并早期冠状动脉异常患儿的I/IIa期试验的原理与研究设计（ANAKID试验）
Contemp Clin Trials. 2016 May;48:70-5. doi: 10.1016/j.cct.2016.04.002. Epub 2016 Apr 11.
3
Kawasaki disease with giant aneurysm of left coronary artery and complete occlusion of right coronary artery.川崎病伴左冠状动脉巨大动脉瘤和右冠状动脉完全闭塞。
Cardiol Young. 2020 Apr;30(4):580-581. doi: 10.1017/S1047951120000426. Epub 2020 Mar 4.
4
Severe Late-Onset Kawasaki Disease Successfully Treated With Anakinra.用阿那白滞素成功治疗重度迟发性川崎病。
J Clin Rheumatol. 2020 Mar;26(2):e42-e43. doi: 10.1097/RHU.0000000000000814.
5
High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant.高剂量阿那白滞素治疗婴儿难治性川崎病所致巨噬细胞活化综合征。
BMJ Case Rep. 2019 Aug 4;12(8):e229708. doi: 10.1136/bcr-2019-229708.
6
Effect of dipyridamole on the blood flow in coronary aneurysms resulting from Kawasaki disease.双嘧达莫对川崎病所致冠状动脉瘤血流的影响。
Pediatr Cardiol. 1994 Nov-Dec;15(6):263-7. doi: 10.1007/BF00798118.
7
Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial.阿那白滞素治疗伴有冠状动脉瘤的川崎病患儿：一项 I/IIa 期试验。
J Pediatr. 2022 Apr;243:173-180.e8. doi: 10.1016/j.jpeds.2021.12.035. Epub 2021 Dec 23.
8
Coronary manifestations of Kawasaki Disease in computed tomography coronary angiography.川崎病的冠状动脉计算机断层扫描血管造影表现。
J Cardiovasc Comput Tomogr. 2018 Jul-Aug;12(4):275-280. doi: 10.1016/j.jcct.2017.12.003. Epub 2017 Dec 11.
9
Coronary ostial dilatation after Kawasaki disease.川崎病后冠状动脉开口扩张
Acta Cardiol. 2015 Oct;70(5):605-6. doi: 10.2143/AC.70.5.3110527.
10
Extensive coronary and systemic arterial aneurysm development in severe refractory Kawasaki disease.严重难治性川崎病中广泛的冠状动脉和体动脉动脉瘤形成
Cardiol Young. 2017 Mar;27(2):375-376. doi: 10.1017/S1047951116001967. Epub 2016 Nov 10.

引用本文的文献

1
Advancing multidisciplinary management of pediatric hyperinflammatory disorders.推进儿童高炎症性疾病的多学科管理。
Front Pediatr. 2025 Apr 30;13:1553861. doi: 10.3389/fped.2025.1553861. eCollection 2025.
2
Pyroptosis in Kawasaki disease: from mechanisms to targeted interventions.川崎病中的细胞焦亡：从机制到靶向干预
Front Immunol. 2025 Apr 16;16:1566985. doi: 10.3389/fimmu.2025.1566985. eCollection 2025.
3
Inhibition of IL-1 Ameliorates Cardiac Dysfunction and Arrhythmias in a Murine Model of Kawasaki Disease.白介素-1 抑制可改善川崎病小鼠模型的心脏功能障碍和心律失常。
Arterioscler Thromb Vasc Biol. 2024 Apr;44(4):e117-e130. doi: 10.1161/ATVBAHA.123.320382. Epub 2024 Feb 22.
4
Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.英夫利昔单抗治疗川崎病的疗效和安全性：系统评价和荟萃分析。
Eur J Pediatr. 2024 Apr;183(4):1765-1776. doi: 10.1007/s00431-024-05437-2. Epub 2024 Jan 19.
5
Mitochondrial quality control in health and cardiovascular diseases.健康与心血管疾病中的线粒体质量控制
Front Cell Dev Biol. 2023 Nov 6;11:1290046. doi: 10.3389/fcell.2023.1290046. eCollection 2023.
6
Platelets exacerbate cardiovascular inflammation in a murine model of Kawasaki disease vasculitis.血小板在川崎病血管炎的小鼠模型中加剧心血管炎症。
JCI Insight. 2023 Jul 24;8(14):e169855. doi: 10.1172/jci.insight.169855.
7
Kawasaki Disease and Coronary Artery Involvement: A Narrative Review.川崎病与冠状动脉受累：一篇叙述性综述
Cureus. 2022 Aug 24;14(8):e28358. doi: 10.7759/cureus.28358. eCollection 2022 Aug.
8
Efficacy of Anakinra on Multiple Coronary Arteries Aneurysms in an Infant with Recurrent Kawasaki Disease, Complicated by Macrophage Activation Syndrome.阿那白滞素对一名复发性川崎病合并巨噬细胞活化综合征婴儿多发冠状动脉瘤的疗效
Children (Basel). 2022 May 5;9(5):672. doi: 10.3390/children9050672.
9
Targeting IRE1 endoribonuclease activity alleviates cardiovascular lesions in a murine model of Kawasaki disease vasculitis.靶向 IRE1 内切核酸酶活性可减轻川崎病血管炎小鼠模型的心血管损伤。
JCI Insight. 2022 Mar 22;7(6):e157203. doi: 10.1172/jci.insight.157203.
10
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3.美国风湿病学会儿童 COVID-19 相关 SARS-CoV-2 与儿童多系统炎症综合征及过度炎症的临床指导：第 3 版
Arthritis Rheumatol. 2022 Apr;74(4):e1-e20. doi: 10.1002/art.42062. Epub 2022 Feb 3.